Please ensure Javascript is enabled for purposes of website accessibility

Why Kodiak Sciences Stock Is Tumbling Today

By Keith Speights - May 10, 2021 at 12:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company provided a first-quarter update with news that it's launching another late-stage clinical study of its lead candidate.

What happened

Shares of Kodiak Sciences (KOD 14.07%) were tumbling 11.1% lower as of 12:07 p.m. EDT on Monday. The decline came after the company provided its first-quarter update.

So what

Kodiak reported a net loss in Q1 of $0.98 per share with no revenue. That bottom-line result was a little worse than the average analysts' estimate of a net loss of $0.97 per share. However, the sell-off of the biotech stock probably stemmed more from another announcement.

The company already has four pivotal late-stage studies in progress for lead candidate KSI-301. Two of those studies target diabetic macular edema (DME), an eye disease that's a complication of diabetes. One targets retinal vein occlusion (RVO). Kodiak also has a phase 3 study under way evaluating KSI-301 in treating wet age-related macular degeneration (AMD). Today, the drugmaker announced that it's adding another late-stage study in the wet AMD indication.

Letters AMD next to a plastic eyeball and on top of an eye chart

Image source: Getty Images.

Kodiak said that physicians have told it they'd like for KSI-301 to be able to be given at more frequent dosing for patients with wet AMD. As a result, the company is launching a study that will evaluate monthly dosing of KSI-301. It expects to begin enrollment this summer and use data from the study in its regulatory filing.

Investors appear to be concerned that Kodiak's regulatory submission will be later than they initially hoped. However, Kodiak thinks that the addition of the new clinical study will position KSI-301 for the broadest possible label and help make the drug a bigger commercial success if approved.

Now what

Kodiak expects to complete patient recruitment in the fourth quarter for its two DME studies and its RVO study. The company also said it's on track for the last patient visit related to the primary efficacy endpoint in its initial wet AMD late-stage study before year-end.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Kodiak Sciences Inc. Stock Quote
Kodiak Sciences Inc.
$11.11 (14.07%) $1.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.